OX40 Agonist and Immunotherapy in Advanced Solid Tumors
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors
Clin. Cancer Res 2020 Dec 21;[EPub Ahead of Print], M Gutierrez, V Moreno, KM Heinhuis, AJ Olszanski, A Spreafico, M Ong, Q Chu, RD Carvajal, J Trigo, MO De Olza, M Provencio, FY De Vos, F De Braud, S Leong, D Lathers, R Wang, P Ravindran, Y Feng, P Aanur, I MeleroFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.